ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
Scientific Research Publishing

Cumulative Link Modeling of Ordinal Outcomes in the National Health Interview Survey Data: Application to Depressive Symptom Severity ()

Williams, A. and Louis, L. (2026) Cumulative Link Modeling of Ordinal Outcomes in the National Health Interview Survey Data: Application to Depressive Symptom Severity. Journal of Data Analysis and ...

Best of the Long View 2025: Investing

Listen and subscribe to Morningstar’s The Long View from your mobile device: Apple Podcasts | Spotify Hi, and welcome to The Long View. I’m Dan Lefkovitz, strategist for Morningstar Indexes. In this ...